41 results on '"Cappelli, Luca Vincenzo"'
Search Results
2. Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities
3. Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
4. A case of familial donor-derived acute myeloid leukemia with underlying pre-leukemic mutations
5. Editorial: Novelties in acute myeloid leukemia: from biology to clinical applications.
6. Peripheral T cell lymphomas: from the bench to the clinic
7. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study
8. DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern
9. S235: GENERATION AND APPLICATION OF A LIVING T-CELL LYMPHOMA PATIENT-DERIVED TUMOR XENOGRAFT BIOREPOSITORY
10. IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies
11. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature
12. Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature
13. A Patient-Derived T-Cell Lymphoma Biorepository Uncovers New Pathogenetic Mechanisms and Host-Related Therapeutic Vulnerabilities
14. Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
15. Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment
16. A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments
17. Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens
18. Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
19. Metabolic and immune markers for precise monitoring of COVID-19 severity and treatment
20. Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
21. Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma
22. TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
23. In Vivo and Ex Vivo Patient‐Derived Tumor Xenograft Models of Lymphoma for Drug Discovery
24. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression
25. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries
26. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
27. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression.
28. DNMT3A and NPM1 Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity
29. NPM1 Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis
30. TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment
31. Current and future therapeutic approaches for the treatment of follicular lymphoma
32. Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome
33. DNMT3Amutations are over-represented in young adults with NPM1mutated AML and prompt a distinct co-mutational pattern
34. Comparative analysis between RQ- PCR and digital droplet PCR of BCL2/ IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
35. DNMT3Aand NPM1Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity
36. NPM1Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis
37. TP53Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment
38. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.
39. A Case of Central Venous Catheter-Related Candida parapsilosis Fungemia Evolved to Disseminated Infection in a Neutropenic Patient with Blast Crisis of Chronic Myeloid Leukemia.
40. Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia.
41. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.